AI Article Synopsis

  • The study examines the effects of prodigiosin (PG) on two small cell lung carcinoma (SCLC) cell lines, including a doxorubicin-resistant variant that overexpresses MRP-1.
  • PG triggers apoptosis by activating a series of biological processes, including cytochrome c release and caspase activation, in both cell lines tested.
  • The findings suggest that PG may be effective for treating lung cancer as it effectively counters the challenges posed by MRP-1 related multidrug resistance.

Article Abstract

In the present study, we describe the cytotoxicity of the new drug prodigiosin (PG) in two small cell lung carcinoma (SCLC) cell lines, GLC4 and its derived doxorubicin-resistant GLC4/ADR cell line, which overexpresses multidrug-related protein 1 (MRP-1). We observed through Western blot that PG mediated cytochrome c release, caspase cascade activation and PARP cleavage, thereby leading to apoptosis in a dose-response manner. MRP-1 expression increased after PG treatment, although that does not lead to protein accumulation. The MTT assay showed no difference in sensitivity to PG between the two cell lines. Our results support PG as a potential drug for the treatment of lung cancer as it overcomes the multidrug resistance phenotype produced by MRP-1 overexpression.

Download full-text PDF

Source
http://dx.doi.org/10.1097/00001813-200504000-00005DOI Listing

Publication Analysis

Top Keywords

small cell
8
cell lung
8
glc4/adr cell
8
cell lines
8
cell
6
high cytotoxic
4
cytotoxic sensitivity
4
sensitivity human
4
human small
4
lung doxorubicin-resistant
4

Similar Publications

Spatially ordered recruitment of fast muscles in accordance with movement strengths in larval zebrafish.

Zoological Lett

January 2025

National Institutes of Natural Sciences, Exploratory Research Center On Life and Living Systems (ExCELLS), National Institute for Basic Biology, Okazaki, Aichi, 444-8787, Japan.

In vertebrates, skeletal muscle comprises fast and slow fibers. Slow and fast muscle cells in fish are spatially segregated; slow muscle cells are located only in a superficial region, and comprise a small fraction of the total muscle cell mass. Slow muscles support low-speed, low-force movements, while fast muscles are responsible for high-speed, high-force movements.

View Article and Find Full Text PDF

Non-coding RNAs secreted by renal cancer include piR_004153 that promotes migration of mesenchymal stromal cells.

Cell Commun Signal

January 2025

Centre of Postgraduate Medical Education, Centre of Translation Research, Department of Biochemistry and Molecular Biology, ul. Marymoncka 99/103, Warsaw, 01-813, Poland.

Background: Renal cell cancer (RCC) is the most common and highly malignant subtype of kidney cancer. Mesenchymal stromal cells (MSCs) are components of tumor microenvironment (TME) that influence RCC progression. The impact of RCC-secreted small non-coding RNAs (sncRNAs) on TME is largely underexplored.

View Article and Find Full Text PDF

Evaluation of an enhanced ResNet-18 classification model for rapid On-site diagnosis in respiratory cytology.

BMC Cancer

January 2025

Department of Pathology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, 325000, Zhejiang, China.

Objective: Rapid on-site evaluation (ROSE) of respiratory cytology specimens is a critical technique for accurate and timely diagnosis of lung cancer. However, in China, limited familiarity with the Diff-Quik staining method and a shortage of trained cytopathologists hamper utilization of ROSE. Therefore, developing an improved deep learning model to assist clinicians in promptly and accurately evaluating Diff-Quik stained cytology samples during ROSE has important clinical value.

View Article and Find Full Text PDF

Background: With extended gefitinib treatment, the therapeutic effect in some non-small cell lung cancer (NSCLC) patients declined with the development of drug resistance. Aidi injection (ADI) is utilized in various cancers as a traditional Chinese medicine prescription. This study explores the molecular mechanism by which ADI, when combined with gefitinib, attenuates gefitinib resistance in PC9GR NSCLC cells.

View Article and Find Full Text PDF

Background: To date, there remains a paucity of comparative investigations pertaining to preoperative immunochemotherapy and conventional chemotherapy in the context of limited-stage small-cell lung cancer (LS-SCLC) patients. This study conducted a comprehensive comparative assessment concerning the safety and efficacy profiles of preoperative immunochemotherapy and chemotherapy in individuals diagnosed with stage I-IIIB SCLC.

Methods: This investigation collected 53 consecutive patients diagnosed with LS-SCLC spanning stage I to IIIB who underwent preoperative immunochemotherapy or conventional chemotherapy at our hospital from January 2019 to July 2021.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!